Construct validation of patient global impression of severity (PGI-S) and improvement (PGI-I) questionnaires in the treatment of men with lower urinary tract symptoms secondary to benign prostatic hyperplasia
Lower urinary tract symptoms (LUTS) in aging men are often associated with benign prostatic hyperplasia (BPH). While regulatory evaluations of treatment benefit require an assessment of specific symptoms, a simpler approach to measuring patients’ perceptions of severity and symptom change may be particularly useful for clinical practice. The aim of this study was to provide evidence of the validity of the 1-item Patient Global Impression of Severity (PGI-S) and Improvement (PGI-I) questionnaires for use as outcome measures in the treatment of BPH-LUTS.
This was a secondary analysis of data from 4 randomized placebo-controlled 12-week trials evaluating tadalafil for the treatment of BPH-LUTS (N=1694). Visit 2 (V2 [beginning of a 4-week placebo lead-in period]) and endpoint assessments included International Prostate Symptom Score (IPSS), IPSS Quality of Life Index (IPSS-QoL), BPH Impact Index (BII), and peak urine flow (Qmax). PGI-S was only administered at V2 and PGI-I only at endpoint. Associations between the PGI-S or the PGI-I and the other assessments were analyzed by calculating Spearman rank correlation coefficients and performing analysis of variance (ANOVA).
Spearman correlation coefficients were 0.43, 0.43, 0.53, and −0.09, between the PGI-S and IPSS, IPSS-QoL, BII, and Qmax baseline results (all P<0.001). Similar results were seen across race, ethnicity, and baseline severity (moderate LUTS versus severe LUTS). IPSS, IPSS-QoL, BII baseline scores (P <0.001) and Qmax values (P=0.003) were significantly different among the 4 PGI-S severity levels. Spearman correlation coefficients were 0.56, 0.53, 0.47 and −0.15 between the PGI-I and change in IPSS, IPSS-QoL, BII scores, and Qmax values from baseline to endpoint (all P<0.001). Similar results were seen across race, ethnicity, and baseline severity. Change in IPSS, IPSS-QoL, BII scores, and Qmax values (P<0.001) were significantly different among the PGI-I levels (i.e., patient perception of change in urinary symptoms).
This study demonstrated patients’ overall perceptions of their severity and change in BPH-LUTS can be captured in a way that is simple, valid, and easily administered in a research setting or clinical practice. Clinical parameters are weakly associated with patients’ perception of urinary symptoms, emphasizing the importance of a patient-reported assessment in the evaluation of BPH-LUTS treatment benefit.
- Homma Y, Kawabe K, Tsukamoto T, Yamanaka H, Okada K, Okajima E, Yoshida O, Kumazawa J, Fang-Liu G, Lee C, Hsu T, Cruz RC, Tantiwang A, Lim PH, Sheikh MA, Bapat SD, Marshall VR, Tajima K, Aso Y: Epidemiologic survey of lower urinary tract symptoms in Asia and Australia using the international prostate symptom score. Int J Urol 1997, 4:40-46. CrossRef
- Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, van Kerrebroeck P, Victor A, Wein A: Standardisation Sub-committee of the International Continence Society. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002,21(2):167-178. CrossRef
- Barry MJ, Fowler FJ Jr, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, Cockett AT: The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 1992,148(5):1549-1557.
- [AUA] American Urological Association Web site: Guideline on the management of benign prostatic hyperplasia (BPH). 2012. http://www.auanet.org/content/guidelines-and-quality-care/clinical-guidelines/main-reports/bph-management/chap_1_GuidelineManagementof(BPH).pdf.
- Barry MJ: Evaluation of symptoms and quality of life in men with benign prostatic hyperplasia. Urology 2001,58(6 Suppl 1):25-32. CrossRef
- Angalakuditi M, Seifert RF, Hayes RP, O'Leary MP, Viktrup L: Measurement properties of the benign prostatic hyperplasia impact index in tadalafil studies. Health Qual Life Outcomes 2010, 8:131. CrossRef
- Kingery L, Martin ML, Naegeli AN, Khan S, Viktrup L: Content validity of the Benign Prostatic Hyperplasia Impact Index (BII); a measure of how urinary trouble and problems associated with BPH may impact the patient. Int J Clin Pract 2012,66(9):883-890. CrossRef
- Guy W: ECDEU Assessment Manual for Psychopharmacology. Rockville (MD): National Institute of Mental Health; 1976:217-222. 313-331
- Yalcin I, Bump RC: Validation of two global impression questionnaires for incontinence. Am J Obstet Gynecol 2003, 189:98-101. CrossRef
- Srikrishna S, Robinson D, Cardozo L: Validation of the Patient Global Impression of Improvement (PGI-I) for urogenital prolapse. Int Urogynecol J 2010,21(5):523-528. CrossRef
- Arnold LM, Clauw D, Wang F, Ahl J, Gaynor PJ, Wohlreich MM: Flexible dosed duloxetine in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. J Rheumatol 2010,37(12):2578-2586. CrossRef
- Porst H, Kim ED, Casabé AR, Mir V, Secrest RJ, Xu L, Sundin DP, Viktrup L, LVHJ study team: Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial. Eur Urol 2011,60(5):1105-1113.
- Egerdie RB, Auerbach S, Roehrborn CG, Costa P, Garza MS, Esler AL, Wong DG, Secrest RJ: Tadalafil 2.5 or 5 mg Administered Once Daily for 12 Weeks in Men with Both Erectile Dysfunction and Signs and Symptoms of Benign Prostatic Hyperplasia: Results of a Randomized, Placebo-Controlled, Double-Blind Study. J Sex Med 2012,9(1):271-281. CrossRef
- Yokoyama O, Yoshida M, Kim SC, Wang C-J, Imaoka T, Morisaki Y, Viktrup L: Efficacy and safety of tadalafil in Asian men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: A phase III randomized controlled study. Int J Urol 2012. Epub ahead of print
- Kim SC, Park JK, Kim SW, Lee SW, Ahn TY, Kim JJ, Paick JS, Park NC, Park K, Min KS, Kraus SR, Secrest RJ, Elion-Mboussa A, Viktrup L: Tadalafil administered once daily for treatment of lower urinary tract symptoms in Korean men with benign prostatic hyperplasia: Results from a placebo-controlled pilot study using tamsulosin as an active control. LUTS 2011,3(2):86-93.
- Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S, Coyne K, Kelleher C, Hampel C, Artibani W, Abrams P: Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006,50(6):1306-1315. CrossRef
- Spearman CE: The proof and measurement of association between two things. Am J Psychol 1904, 15:72-101. CrossRef
- Guilford JP, Fruchter B: Fundamental Statistics in Psychology and Education. New York: McGraw-Hill; 1973.
- Lepor H, Williford WO, Barry MJ, Haakenson C, Jones K: The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. J Urol 1998,160(4):1358-1367. CrossRef
- FDA Guidance: Guidance for Industry. Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. 2012. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf.
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2490/12/30/prepub
- Construct validation of patient global impression of severity (PGI-S) and improvement (PGI-I) questionnaires in the treatment of men with lower urinary tract symptoms secondary to benign prostatic hyperplasia
- Open Access
- Available under Open Access This content is freely available online to anyone, anywhere at any time.
- Online Date
- November 2012
- Online ISSN
- BioMed Central
- Additional Links
- Patient global impression scale
- Lower urinary tract symptoms
- Construct validity